Inhaled corticosteroids for the treatment of COVID-19

Mona Bafadhel; Rosa Faner; Camille Taillé; Richard E.K. Russell; Peter J. Barnes; Alvar Agustí; Tobias Welte

doi:10.1183/16000617.0099-2022

Inhaled corticosteroids for the treatment of COVID-19

Mona Bafadhel^*, Rosa Faner, Camille Taillé, Richard E.K. Russell, Peter J. Barnes, Alvar Agustí, Tobias Welte

^*Corresponding author for this work

Peter Gorer Department of Immunobiology

Research output: Contribution to journal › Review article › peer-review

6 Citations (Scopus)

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.

Original language	English
Article number	220099
Journal	European Respiratory Review
Volume	31
Issue number	166
DOIs	https://doi.org/10.1183/16000617.0099-2022
Publication status	Published - 31 Dec 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1183/16000617.0099-2022

Cite this

@article{df2101354e2541218597c5cef602de04,

title = "Inhaled corticosteroids for the treatment of COVID-19",

abstract = "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.",

author = "Mona Bafadhel and Rosa Faner and Camille Taill{\'e} and Russell, {Richard E.K.} and Barnes, {Peter J.} and Alvar Agust{\'i} and Tobias Welte",

note = "Funding Information: Support statement: Medical writing support, under the direction of the authors, was provided by Sharon Gill, PhD, CMC Connect, a division of IPG Health Medical Communications and was funded by AstraZeneca in accordance with Good Publication Practice (GPP3) guidelines [109]. Funding information for this article has been deposited with the Crossref Funder Registry. Publisher Copyright: {\textcopyright} The authors 2022.",

year = "2022",

month = dec,

day = "31",

doi = "10.1183/16000617.0099-2022",

language = "English",

volume = "31",

journal = "European Respiratory Review",

issn = "0905-9180",

publisher = "European Respiratory Society",

number = "166",

}

TY - JOUR

T1 - Inhaled corticosteroids for the treatment of COVID-19

AU - Bafadhel, Mona

AU - Faner, Rosa

AU - Taillé, Camille

AU - Russell, Richard E.K.

AU - Barnes, Peter J.

AU - Agustí, Alvar

AU - Welte, Tobias

N1 - Funding Information: Support statement: Medical writing support, under the direction of the authors, was provided by Sharon Gill, PhD, CMC Connect, a division of IPG Health Medical Communications and was funded by AstraZeneca in accordance with Good Publication Practice (GPP3) guidelines [109]. Funding information for this article has been deposited with the Crossref Funder Registry. Publisher Copyright: © The authors 2022.

PY - 2022/12/31

Y1 - 2022/12/31

N2 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.

AB - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused severe illness and mortality for millions worldwide. Despite the development, approval and rollout of vaccination programmes globally to prevent infection by SARS-CoV-2 and the development of coronavirus disease 2019 (COVID-19), treatments are still urgently needed to improve outcomes. Early in the pandemic it was observed that patients with pre-existing asthma or COPD were underrepresented among those with COVID-19. Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19. This review summarises the evidence supporting the beneficial effects of ICS on outcomes in patients with COVID-19 and explores the potential protective mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=85143111106&partnerID=8YFLogxK

U2 - 10.1183/16000617.0099-2022

DO - 10.1183/16000617.0099-2022

M3 - Review article

C2 - 36450371

AN - SCOPUS:85143111106

SN - 0905-9180

VL - 31

JO - European Respiratory Review

JF - European Respiratory Review

IS - 166

M1 - 220099

ER -

Inhaled corticosteroids for the treatment of COVID-19

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this